The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 29, 2023

Filed:

Jan. 31, 2019
Applicant:

Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, CN;

Inventors:

Caixia Gao, Beijing, CN;

Huawei Zhang, Shandong Province, CN;

Shuai Jin, Beijing, CN;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/64 (2006.01); C12N 15/11 (2006.01); C12N 9/22 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C12N 15/11 (2013.01); C12N 9/22 (2013.01); C12N 15/902 (2013.01); C12N 2310/20 (2017.05); C12N 2510/02 (2013.01); C12N 2800/80 (2013.01);
Abstract

Provided are an improved genome editing system and a method that has high specificity, which are capable of obtaining stable mutation types. The system includes an expression construct including a coding sequence of a gRNA targeting at least one genomic target sequence; an expression construct including a coding sequence of a CRISPR nuclease; and an expression construct including a coding sequence for a gRNA targeting a target sequence within the coding sequence of the CRISPR nuclease. Upon introduction into the cell, the gRNA targeting the at least one genomic target sequence directs the CRISPR nuclease to the at least one genomic target sequence and results in one or more mutations in the genomic target sequence, and the gRNA targeting a target sequence within the coding sequence of the CRISPR nuclease directs the CRISPR nuclease to the target sequence within the coding sequence of the CRISPR nuclease and results in an inactivating mutation of the CRISPR nuclease.


Find Patent Forward Citations

Loading…